Navigation Links
Savient Reaches Agreement To Sell Substantially All Assets To Crealta Pharmaceuticals
Date:12/11/2013

#160;We believe this is a meaningful step in Crealta's journey to becoming a leading specialty pharmaceutical company."

The transaction is subject to certain closing conditions, including approval from the Court and the termination of the waiting period under Hart-Scott-Rodino.  Upon the completion of the sale, Savient's previously announced agreement with US WorldMeds, LLC and Sloan Holdings C.V. will terminate in accordance with its terms.  Additional information, court filings and other documents related to this process, is available through Savient's claims agent, the Garden City Group, at www.gcginc.com/cases/svnt or 866-297-1238. 

Crealta was established in August 2013 in partnership with GTCR, one of the nation's leading private equity firms.

Skadden, Arps, Slate, Meagher & Flom LLP and Cole, Schotz, Meisel, Forman & Leonard P.A. are serving as Savient's legal advisors, and Lazard is serving as its financial advisor.  Kirkland & Ellis LLP is serving as legal advisor to Crealta.

KRYSTEXXA® IMPORTANT SAFETY INFORMATION

The following information is provided in both the U.S. and European prescribing information.

KRYSTEXXA® is not indicated for the treatment of asymptomatic hyperuricemia. KRYSTEXXA® is indicated for adults who have tried or cannot take oral gout medications and still have high uric acid levels and signs and symptoms of gout. Patients who have a genetic condition known as G6PD deficiency should not use KRYSTEXXA®.

Discontinue oral urate-lowering therapies before instituting KRYSTEXXA® and do not institute oral urate-lowering therapy while the patient is on KRYSTEXXA® therapy.

Warnings and Precautions:

  • Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA®. KRYSTEXXA® sh
    '/>"/>

SOURCE Savient Pharmaceuticals, Inc.; Crealta Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Savient Reaches Agreement On Use Of Cash Collateral
2. Savient Pharmaceuticals Reports Second Quarter 2013 Financial Results
3. Savient Pharmaceuticals Reports First Quarter 2013 Financial Results
4. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2012 Financial Results Conference Call on Tuesday, March 19, 2013
5. Savient Announces the Election of Robert G. Savage to its Board of Directors
6. Savient Pharmaceuticals Reports Third Quarter 2012 Financial Results
7. Savient Pharmaceuticals to Present at the 6th Annual Imperial Capital Global Opportunities Conference
8. Savient Pharmaceuticals to Present at the Rodman & Renshaw 14th Annual Healthcare Conference
9. Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
10. Savient Pharmaceuticals Adopts Stockholder Rights Plan
11. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... campaign launched today highlights the clear choice policymakers in states ... Medicaid program: cut benefits for patients or billions in overpayments ... save $33 billion over the next decade by cutting ... like those in Medicare and commercial plans. ...
... RENO, Nev., June 15, 2011 Visual Healthcare Corp. (the ... announce today that it expects revenues for the fourth quarter ... mid-range of the current guidance is a record high since ... 2011. Based on these figures the Company can provide further ...
Cached Medicine Technology:The Medicaid Choice: Cut Benefits for Patients or Overpayments to Independent Drugstores 2Visual Healthcare Provides Fourth Quarter Revenue Guidance 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... three months the trends for evening dresses shift ... one of the hottest styles in the next few months.” ... releases 26 A-line sweetheart evening dresses, and announces the availability ... are trying our best to help a lady to show ... affordable prices, we provide discounted delivery costs to our customers ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company ... collection of discounted prom dresses, most of which are ... of the company, the promotion is valid until Jan. ... expand the UK market. , The prom dresses in ... and styles: A-line strapless, empire strapless chiffon, one shoulder, ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... HANGZHOU, China, Nov. 24 Tigermed Consulting ... in China, announced that it has,established strategic ... Russia and,LSK in Korea respectively to integrate ... global clinical trial network. This new strategic ...
... , QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - ... high-value cancer diagnostic tests and delivering laboratory services, announced ... the Company, will be presenting a company overview at ... Wednesday, December 3, 2008, at 4:00 PM (ET). This ...
... victorious,politicians will go to work on America,s most pressing ... have to wait on their elected,officials to start improving ... to their doctors, according to patient satisfaction expert,Dr. Steve ... don,t know whether politicians listen to their constituents on ...
... days, many are feeling,financially, emotionally and physically stressed. Your ... Feeling spiritual seems the farthest thing,from your mind. In ... social,networking sites, we remain connected 24/7, yet alone. Is ... is the new ,old, trend?,Join the One Spirit(R) Book ...
... are anything but. Faced with health problems, financial issues ... adults 65 years and older suffer from depression. While ... the problem, another group - centenarians - has been left ... depression hasn,t been studied thoroughly in this group," said Adam ...
... vein thrombosis (DVT) may help dissolve blood clots in less ... Emory University. The study will be presented Sunday, Nov. 23, ... "These clots are a main cause of both heart attacks ... the better," says Karthikeshwar Kasirajan, MD, assistant professor of surgery ...
Cached Medicine News:Health News:Tigermed Forms Strategic Partnerships With Leading CROs in Russia and South Korea 2Health News:DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008 2Health News:Politicians May Not Listen ... But Doctors Do, Says DrScore 2Health News:Engaging In Life with One Spirit Book Club 2Health News:Bittersweet milestones 2Health News:Ultrasound waves aid in rapid treatment of DVT 2
... only control for monitoring total ... fluid samples performed manually using ... an aid for identifying the ... pathological condition present in the ...
... use with Leica Unistat and ... and all automated bilirubin methods ... AU Series, Cobas, Dimension, Hitachi, ... contain purified bilirubin in a ...
... The Dropper Plus is specifically designed for ... room temperature stability eliminates storage problems and ... without refrigeration. A new feature is the ... provided for all analytes; qualitative results for ...
... the ultimate in convenience for urinalysis quality ... DipandSpin is a combination product for dipstick, ... feature is the addition of creatinine and ... as well as for all analytes; qualitative ...
Medicine Products: